methsuximide
Sign in to saveAlso known as Celontin®, Petinutin®, 1,3-Dimethyl-3-phenylsuccinimide, Methsuximid, N,2-Dimethyl-2-phenylsuccinimide, Mesuximida, 1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione, Mesuximide
Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland) and Celontin (United States). The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.
Research
113 papers- Methsuximide.2012
- Methsuximide for refractory complex partial seizures.Neurology · 1981
- Methsuximide-induced movement disorder.Pediatrics · 1991
- Methsuximide reduces valproic acid serum levels.Therapeutic drug monitoring · 2001
- Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction.Epilepsia · 2000
via PubMed
Wikidata facts
- Mass
- 203.095
Show 4 more facts
- defined daily dose
- 0.9
- chemical formula
- C₁₂H₁₃NO₂
- canonical SMILES
- CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2
- Commons category
- Mesuximide
Sources (6)
via Wikidata · CC0
~1 min read
Article
2 sectionsContents
- Medical use
- References
Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland) and Celontin (United States). The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.
==Medical use== The medical use is indicated for the control of absence seizures that are refractory to other drugs.